Medicare AdvantageCoverageMedium impact
MA11.007b, Islet Cell Transplantation, including use of Donislecel-jujn (Lantidra)
Independence Blue Cross·Endocrinology, Transplant Surgery, Critical Care·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Policy MA11.007b has been reissued effective 03/05/2025, addressing islet cell transplantation coverage including the new therapy Donislecel-jujn (Lantidra). The billing team must review this updated policy to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for islet cell transplant procedures and this newly approved cellular therapy.
Action Required
By 03/05/2025: Billing and clinical teams must review the complete policy text at the provided URL to identify specific coverage requirements, prior authorization mandates, and approved billing codes for islet cell transplantation and Donislecel-jujn (Lantidra). Update authorization workflows, encounter forms, and billing system rules accordingly. Ensure all claims for islet cell transplants submitted on or after 03/05/2025 comply with the reissued policy requirements. Contact the policy source if specific billing codes or authorization procedures are unclear.